Showing 1801-1810 of 3038 results for "".
- CoFi Announces 300 Eye Care Practices Now Use CoFi’s Compliant Co-Management Payments Tool for Ophthalmology Procedureshttps://modernod.com/news/cofi-announces-300-eye-care-practices-now-use-cofis-compliant-co-management-payments-tool-for-ophthalmology-procedures/2480490/CoFi, a provider of a multi-party payments platform for elective medical procedures, announced the growing adoption of its co-management payment solution for ophthalmology procedures with more than 300 practices now using CoFi. Throughout ophthalmology, there i
- Notal Vision Monitoring Center Reports AI Analysis of 10 Million ForeseeHome AMD Home Monitoring Testshttps://modernod.com/news/notal-vision-monitoring-center-reports-ai-analysis-of-10-million-foreseehome-amd-home-monitoring-tests/2480482/The Notal Vision Monitoring Center celebrates the artificial intelligence (AI) based analysis of the ten millionth test performed by over 20,000 patients with the FDA-cleared ForeseeHome devic
- CXL Ophthalmics to Present Phase 2 Clinical Trial Results in Epi-On Cross-linking on November 14 at American Academy of Ophthalmologyhttps://modernod.com/news/cxl-ophthalmics-to-present-phase-2-clinical-trial-results-in-epi-on-cross-linking-on-november-14-at-american-academy-of-ophthalmology/2480421/CXL Ophthalmics announced that the results of CXL-005, a phase 2 Trial in transepithelial (Epi-On) cross-linking, will be featured in the “Hot Topics 2021” session at AAO on November
- I-MED Pharma Set to Launch its Dry Eye Product Portfolio in the UShttps://modernod.com/news/i-med-pharma-set-to-launch-its-innovative-dry-eye-product-portfolio-in-the-us/2480408/I-MED Pharma USA announced it is bringing its dry eye product portfolio to the US market and will sell directly to eye care professionals. The dry eye portfolio includes I-DROP artificial tears, I-LID ’N LASH ocular hy
- Novartis to Sell Roche Stake for $20.7 Billionhttps://modernod.com/news/novartis-to-sell-roche-stake-for-207-billion/2480406/Novartis said Thursday that it agreed to sell its stake in Roche for $20.7 billion, with the proceeds to be used "in line with capital allocation priorities to enhance strong returns to shareholders," according to a FirstWord repor
- Oyster Point’s Tyrvaya Nasal Spray for Dry Eye Disease is Now Available at US Regional Wholesalershttps://modernod.com/news/oyster-points-tyrvaya-nasal-spray-for-dry-eye-disease-is-now-available-at-us-regional-wholesalers/2480399/Oyster Point Pharma announced that Tyrvaya (varenicline solution) Nasal Spray 0.03 mg is now available at US regional wholesalers for distribution to pharmacies. The FDA approved Tyrvaya Nasal Spray for the treatment of the signs and symptoms of dry eye disease on O
- Registration Now Open for International Sports Vision Association 6th Annual Conferencehttps://modernod.com/news/registration-now-open-for-international-sports-vision-association-6th-annual-conference/2480360/Registration is now open for Elevating Athletic Performance<
- Novartis Announces FDA and EMA Filing Acceptances of Beovu for Patients with Diabetic Macular Edemahttps://modernod.com/news/novartis-announces-fda-and-ema-filing-acceptances-of-beovu-for-patients-with-diabetic-macular-edema/2480351/Novartis announced that the FDA has accepted the company’s supplemental biologics license application (BLA) and that the European Medicines Agency (EMA) has validated the type-II variation application for Beovu (brolucizumab) 6 mg for the treatment of diabetic macular edema (DME).
- Outlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO Trialhttps://modernod.com/news/outlook-therapeutics-reports-new-positive-12-month-safety-data-from-pivotal-phase-3-norse-two-trial/2480308/Outlook Therapeutics announced new 12-month safety data from the pivotal phase 3 NORSE TWO trial that further confirm the strong safety profile in this study of ONS-5010/Lytenava (bevacizumab-vikg) for treatment of wet age-related macular degeneration (AMD). In August 2021, Outlook Ther
- Nicox’s NCX 470 Shows Retinal Cell Protection in a Nonclinical Modelhttps://modernod.com/news/nicoxs-ncx-470-shows-retinal-cell-protection-in-a-nonclinical-model/2480307/Nicox reported new data on NCX 470 in a nonclinical model of retinal cell damage induced by endothelin-1 (ET-1). NCX 470, Nicox’s lead clinical candidate, is a nitric oxide-donating prostaglandin analog currently in phase 3 clinical development for lowering IOP in patients with op